Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan

Thornton, Sheila J.; Piecuch, Anna; Lynd, Larry D.; Wasan, Ellen K.

doi:10.3109/03639041003796648

Cited by 23 publications

(29 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment recommendations for visceral leishmaniasis vary by region [Thornton et al, 2010]. Pentavalent antimonial compounds were considered the treatment of choice for decades, but the development of resistance among L. donovani isolates in countries such as India and serious side effects have limited their use in many areas [Berman, 2005; Herwaldt et al, 1992].…”

Section: The Challenges Of Treating Leishmaniasismentioning

confidence: 99%

New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas

Dupnik

Nascimento

Rodrigues-Neto

et al. 2011

Drug Development Research

View full text Add to dashboard Cite

Visceral leishmaniasis [VL] represents a major public health problem in many areas of the world. This review focuses on the impact of periurbanization on the epidemiology and treatment of VL, using Brazil as an example. VL continues to be mostly a disease of poverty with impact on families. However, the disease has expanded in Latin America, with foci reported as far south as Argentina. There is an increasing overlap of Leishmania infantum chagasi and HIV infections and other immunosuppressive conditions, resulting in VL emerging as an opportunistic infection. This new setting poses new challenges for VL disease control and patient management.

show abstract

Section: The Challenges Of Treating Leishmaniasismentioning

confidence: 99%

New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas

Dupnik

Nascimento

Rodrigues-Neto

et al. 2011

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…The selective activity of AMB against fungi and leishmania instead of mammalian cells is because of its higher affinity for ergosterol and episterol, which are found in parasite membranes, than for cholesterol, which is the mammalian sterol (4,5). However, treatment with AMB is restricted by its dose-dependent toxicity and low therapeutic index in humans (6).…”

mentioning

confidence: 99%

“…The cost of injectable GMP-grade cholesterol is higher than that of plant-derived stigmasterol because of its animal origin and the special processing that is required to make the cholesterol free of the agents of bovine spongiform encephalopathy/transmissible spongiform encephalopathy (BSE/TSE) and the related analysis procedures, which make the final product expensive (EMA BSE/TSE guideline EMA/410/01, revision 3). Thus, the use of stigmasterol, a plant-derived sterol, as an alternative to cholesterol might decrease the overall cost of the liposomal AMB preparation and reduce the risk of transfer of prions from mammal-derived cholesterol that might occur (6).…”

mentioning

confidence: 99%

Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl- sn -Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B

Iman

Huang

Alavizadeh

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

1,2-Distigmasterylhemisuccinoyl-sn-glycero-3-phosphocholine (DSHemsPC) is a new lipid in which two molecules of stigmasterol (an inexpensive plant sterol) are covalently linked via a succinic acid to glycerophosphocholine. Our previous study revealed that liposome (Lip)-intercalated amphotericin B (AMB) prepared from DSHemsPC (DSHemsPC-AMB-Lip) possesses excellent colloidal properties and in vitro antifungal and antileishmanial activities similar to those of the liposomal AMB preparation AmBisome. The aim of this study was to determine the biodistribution and evaluate the antileishmanial effects of DSHemsPC-AMB-Lip in Leishmania majorinfected BALB/c mice. The serum profile and tissue concentrations of AMB were similar in DSHemsPC-AMB-Lip-and AmBisome-treated mice after intravenous (i.v.) injection. Multiple i.v. doses of the micellar formulation of AMB (Fungizone; 1 mg/kg of body weight), DSHemsPC-AMB-Lip (5 mg/kg), and AmBisome (5 mg/kg) were used in L. major-infected BALB/c mouse models of early and established lesions. In a model of the early lesions of cutaneous leishmaniasis (CL), the results indicated that the level of footpad inflammation was significantly (P Ͻ 0.001) lower in mice treated with DSHemsPC-AMB-Lip and AmBisome than mice treated with empty liposomes or 5% dextrose. The splenic and footpad parasite load was also significantly (P Ͻ 0.001) lower in these groups of mice than in control mice that received 5% DW or free liposome. The in vivo activity of DSHemsPC-AMB-Lip was comparable to that of AmBisome, and both provided improved results compared to those achieved with Fungizone at the designated doses. The results suggest that systemic DSHemsPC-AMB-Lip administration may be useful for the treatment of leishmaniasis, and because it costs less to produce DSHemsPC-AMB-Lip than AmBisome, DSHemsPC-AMB-Lip merits further investigation.

show abstract

“…British Columbia who devised the initial formulation, [45][46][47][48][49] iCoTherapeutics are committed to ensuring access to these formulations for treatment of visceral leishmaniasis in some low-income and middle-income countries, while allowing the company to pursue more lucrative highincome markets for treatment of fungal infections.…”

Section: Personal Viewmentioning

confidence: 99%

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries

Loyse

Thangaraj

Easterbrook

et al. 2013

The Lancet Infectious Diseases

163

144

View full text Add to dashboard Cite

Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan

Cited by 23 publications

References 34 publications

New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas

New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas

Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl- sn -Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries

Contact Info

Product

Resources

About